Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease […]

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Respiratory inhaler devices market positioned for notable expansion through 2030, Open PR, July 13, 2027

An article recently published in Open PR notes that inhaler devices are seeing broadening use for managing several respiratory conditions, with pulmonary arterial hypertension listed alongside asthma and COPD as one of the areas of application. The report is about the respiratory inhaler devices market overall — smart/connected inhalers, market size projections (forecast to reach

Respiratory inhaler devices market positioned for notable expansion through 2030, Open PR, July 13, 2027 Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026

Could a new protein become a future treatment target in pulmonary arterial hypertension(PAH)? Researchers have identified a protein called placental growth factor – PlGF – as a possible new driver of pulmonary arterial hypertension (PAH). Although its name suggests it is only involved in pregnancy, placental growth factor is also active in blood vessels and

Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026 Read Post »

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026

Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) is classified as Group 2 pulmonary hypertension by the World Health Organization (WHO). It is a type of heart failure in which the heart still pumps normally but becomes too stiff to fill properly with blood between heartbeats. This can cause pressure to build

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026 Read Post »

PH Update 2026 – Gateway to the 8th World Symposium, Sheraton Ann Arbor, Michigan, USA, October 2, 2026

The PH Update 2026 – Gateway to the 8th World Symposium will bring together experts in Pulmonary Hypertension for a day of scientific discussion, clinical updates and perspectives toward the 8th World Symposium on Pulmonary Hypertension. Click here for programme and to register

PH Update 2026 – Gateway to the 8th World Symposium, Sheraton Ann Arbor, Michigan, USA, October 2, 2026 Read Post »

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026

Natalia Maeva, a patient advocate for pulmonary hypertension, attended the European Respiratory Society (ERS) Presidential Summit in Warsaw in June 2026, participating in sessions on early detection, air quality, tobacco control, climate change and lung health. Having had her own life transformed by access to specialised treatment and lung transplantation, she found the discussions on

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026 Read Post »

The e-book for the May 2026 edition of Transplant International is available online in open access

The e-book for the May 2026 edition of Transplant International is available online in open access at this link The cover features a letter to the editors reporting the impressive summiting of Aconcagua, the highest peak in the Americas, without supplemental oxygen by a lung transplant recipient accompanied by the medico-surgical team from Medical University

The e-book for the May 2026 edition of Transplant International is available online in open access Read Post »

American Thoracic Society (ATS) annual conference 2026 discussions on AI, Innovation, and Humanism in medicine, American Medical Journal, July 1, 2026

The American Thoracic Society (ATS)’s annual international conference, held in Orlando in May 2026, drew over 14,000 participants from more than 100 countries for six days of scientific sessions, clinical trials, and educational programming. The overarching theme was a field in transition — one being reshaped by artificial intelligence and precision medicine, while holding firm

American Thoracic Society (ATS) annual conference 2026 discussions on AI, Innovation, and Humanism in medicine, American Medical Journal, July 1, 2026 Read Post »

Eight months, 230 days,11 countries, 20,000+ km. Lukáš Jakovec’s solo cycling journey for the AfPH “Wheels of Hope” campaign to raise awareness of organ donation and transplant now wraps up!

Lukáš Jakovec set off from Udine, Italy, on 11 October 2025 — a trip he had been planning for over seven years. Two hundred and thirty days and 22,000 km later, with a total elevation gain of roughly 144,000 metres, he rolled into Prague, his home town. Along the way he looped through Italy, including

Eight months, 230 days,11 countries, 20,000+ km. Lukáš Jakovec’s solo cycling journey for the AfPH “Wheels of Hope” campaign to raise awareness of organ donation and transplant now wraps up! Read Post »

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026

Researchers at the Suqian First Hospital in Suqian, Chian, China tested whether adding mindfulness-based stress reduction (MBSR) to standard cardiopulmonary rehabilitation could benefit pulmonary arterial hypertension patients more than usual care alone. Fifty stable patients were split into two groups: one did a 6-week combined mindfulness-based stress reduction and rehab program, the other received standard

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026 Read Post »

Flolan discontinuation confirmed in the UK as of April 2028 – 150 patients in the UK will need to transition to another formulation of epoprostenol, PHA UK News, June 17, 2026

GSK has confirmed it will discontinue Flolan, a drug used to treat pulmonary arterial hypertension, in the UK from 2028 — having already pulled it from the US (see our article on this topic here), and other markets. Around 150 UK patients, including children, currently rely on the drug. With production ending in April 2028

Flolan discontinuation confirmed in the UK as of April 2028 – 150 patients in the UK will need to transition to another formulation of epoprostenol, PHA UK News, June 17, 2026 Read Post »

How to set up and run a patient group with Viber – Transcript

Good evening, everyone: distinguished guests, colleagues, and most importantly, our patient community. We often talk about healthcare in terms of hospitals, medications, and clinical appointments. But when you are living with a rare and complex condition like pulmonary hypertension, or navigating the life-altering journey of a lung transplant, healthcare does not end when you walk

How to set up and run a patient group with Viber – Transcript Read Post »

Managing and distributing your energy throughout the day while living with pulmonary hypertension – Transcript

Welcome to this PEP Talk from the Alliance for Pulmonary Hypertension about managing your energy. My name is Louise Bauman, and 18 years ago I was diagnosed with severe pulmonary arterial hypertension, or PAH. I was in functional class IV and immediately had to start intravenous epoprostenol. At that time, I had a newborn and

Managing and distributing your energy throughout the day while living with pulmonary hypertension – Transcript Read Post »

The butterfly effect, how my PAH diagnosis turned into a support movement – Transcript

Hello everyone, my name is Dina Grajales. I am speaking to you today from Bogotá, Colombia, as a patient living with pulmonary hypertension, president of the Latin Society of Pulmonary Hypertension, and president of the Ayúdanos a Respirar Foundation in Colombia. I am very grateful to the Global Alliance for Pulmonary Hypertension for this invitation

The butterfly effect, how my PAH diagnosis turned into a support movement – Transcript Read Post »

Web-based survey explores patient perspectives on palliative care in pulmonary arterial hypertension in the US, Pulmonary Circulation, June 24, 2026

A US web-based survey involving 200 respondents across 42 states was completed Sept–Oct 2023. The survey explored how patients with pulmonary arterial hypertension (PAH) understand and experience palliative care — which can be offered alongside standard treatment to ease symptoms and improve quality of life, but is underused and often misunderstood. Most respondents equated palliative

Web-based survey explores patient perspectives on palliative care in pulmonary arterial hypertension in the US, Pulmonary Circulation, June 24, 2026 Read Post »

 Introducing the Alliance for Pulmonary Hypertension’s New Board of Directors 2026-2029 We are proud to introduce the new Board of the Alliance for Pulmonary Hypertension — a group of dedicated patient advocates bringing decades of combined experience to our mission of improving life for people living with pulmonary hypertension across the world. Pisana Ferrari, President

Read Post »

TRANSLATE »
Scroll to Top